Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Based on recent U.S. FDA feedback and prior feedback from the UK MHRA, RedHill believes that the ongoing Phase III study with BEKINDA™ for gastroenteritis (the GUARD study) may be...
-
The German Federal Institute for Drugs and Medical Devices (BfArM) has confirmed the positive outcome of the European Decentralized Procedure and informed RedHill and IntelGenx that the European...
-
The National Cancer Institute (NCI) $2 million grant is intended to support the Phase II study with YELIVA™ (ABC294640) for refractory or relapsed multiple myeloma, planned to be initiated...
-
Patients enrolled in the placebo arm of the ERADICATE Hp Phase III study received open-label standard-of-care (SoC) therapy for persistent Helicobacter pylori (H. pylori) infection; results from...
-
TEL-AVIV, Israel, Sept. 2, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
-
The open-label, dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) Phase I study with YELIVA™ (ABC294640) in patients with advanced solid tumors was supported by grants from the...
-
Once granted, the new Israeli patent is expected to be valid through at least 2029, further extending RedHill's global patent portfolio covering RHB-104 RHB-104 is undergoing a first Phase...
-
The publication in the peer-reviewed journal Molecular Cancer Research details promising pre-clinical results suggesting ABC294640 significantly inhibits prostate cancer tumor...
-
TEL-AVIV, Israel, Aug. 12, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
-
Key Highlights Include: Strong cash position of approximately $26.6 million at the end of the second quarter of 2015 and approximately $66 million as of July 28, 2015, following the...